AZD6765 Severe Major Depressive Disorder (MDD) IV

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Major Depressive Disorder
Interventions
DRUG

AZD6765

IV once per dosing day, multiple times during the treatment period

DRUG

Placebo

0.9% saline IV once per dosing day multiple times during the treatment period

Trial Locations (27)

Unknown

Research Site, Little Rock

Research Site, Los Angeles

Research Site, Orange

Research Site, San Diego

Research Site, Santa Ana

Research Site, Hartford

Research Site, New Haven

Research Site, Boca Raton

Research Site, Gainsville

Research Site, Hollywood

Research Site, Jacksonville

Research Site, Atlanta

Research Site, Roswell

Research Site, Hoffman Estates

Research Site, Joliet

Research Site, Overland Park

Research Site, Lake Charles

Research Site, Shreveport

Research Site, Haverhill

Research Site, St Louis

Research Site, Willingboro

Research Site, Albuquerque

Research Site, Rochester

Research Site, East Stroudsburg

Research Site, Philadelphia

Research Site, Austin

Research Site, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY